EGFR and neoplasm: Based on their clinical utility, we proposed that ctDNA assays for plasma EGFR mutation can be used for cancer screening by comparing the EGFR mutational status of tumor samples at the initial diagnosis and the status of plasma samples at 1-month follow-up.